THZ531 | THZ-531 | CAS#1702809-17-3 | CDK12 and CDK13 covalent inhibitor

MedKoo Cat#: 406959 | Name: THZ531

Description:

WARNING: This product is for research use only, not for human or veterinary use.

THZ531 is a covalent CDK12 and CDK13 covalent inhibitor. Cyclin-dependent kinases 12 and 13 (CDK12 and CDK13) play critical roles in the regulation of gene transcription. THZ531 irreversibly targets a cysteine located outside the kinase domain. THZ531 causes a loss of gene expression with concurrent loss of elongating and hyperphosphorylated RNA polymerase II. THZ531 substantially decreases the expression of DNA damage response genes and key super-enhancer-associated transcription factor genes. THZ531 dramatically induced apoptotic cell death. Small molecules capable of specifically targeting CDK12 and CDK13 may thus help identify cancer subtypes that are particularly dependent on their kinase activities.

Chemical Structure

THZ531

CAS#1702809-17-3

Theoretical Analysis

MedKoo Cat#: 406959

Name: THZ531

CAS#: 1702809-17-3

Chemical Formula: C30H32ClN7O2

Exact Mass: 557.2306

Molecular Weight: 558.08

Elemental Analysis: C, 64.57; H, 5.78; Cl, 6.35; N, 17.57; O, 5.73

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,350.00	Ready to ship
500mg	USD 2,850.00	Ready to ship
1g	USD 4,150.00	2 Weeks
2g	USD 6,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

THZ531; THZ-531; THZ 531.

IUPAC/Chemical Name

(R,E)-N-(4-(3-((5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl)amino)piperidine-1-carbonyl)phenyl)-4-(dimethylamino)but-2-enamide

InChi Key

RUBYHLPRZRMTJO-MOVYNIQHSA-N

InChi Code

InChI=1S/C30H32ClN7O2/c1-37(2)15-6-10-27(39)34-21-13-11-20(12-14-21)29(40)38-16-5-7-22(19-38)35-30-33-18-25(31)28(36-30)24-17-32-26-9-4-3-8-23(24)26/h3-4,6,8-14,17-18,22,32H,5,7,15-16,19H2,1-2H3,(H,34,39)(H,33,35,36)/b10-6+/t22-/m1/s1

SMILES Code

O=C(NC1=CC=C(C(N2C[C@H](NC3=NC=C(Cl)C(C4=CNC5=C4C=CC=C5)=N3)CCC2)=O)C=C1)/C=C/CN(C)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#A8T01K15

QC Data

View QC data: current batch, Lot#A8T01K15

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

THZ531 is a covalent inhibitor of both CDK12 and CDK13 with IC50s of 158 nM and 69 nM, respectively.

In vitro activity:

Coincident with THZ531 decreasing the elongating Pol II population, this study found that THZ531 downregulated the expression of certain genes in Jurkat T-ALL. This study found two general signatures of genes that were particularly sensitive to THZ531 treatment. At concentrations leading to complete CDK12 and 13 inhibition, genes encoding factors that regulate transcription were exceptionally sensitive to THZ531. At this concentration, the loss of expression of the most sensitive genes positively correlated with the amount of promoter and enhancer–bound CDK12 with super-enhancer—associated genes being especially sensitive. These data suggest that inhibition of CDK12, like that of CDK7, may provide another means of targeting super –enhancer –associated oncogene expression in various cancers. Additionally, this study found that genes involved in DDR were exquisitely sensitive to low doses of THZ531 and continue to lose expression with escalating doses of THZ531. A similar set of DDR genes was recently shown to be sensitive to loss of CDK12 and 13 cyclin K complexes. In contrast to THZ531 treatment, neither depletion of CDK12 and 13 nor mutations that disrupt complex integrity leads to gross disruption of the larger gene expression program. This discrepancy could be explained by numerous factors. This study favors the explanation that THZ531 treatment effectively creates an inactive or dominant negative CDK12 and 13 complexes, which elicits fundamentally different effects on transcription. However, the modest recovery of wild-type function following expression of CDK12 C1039S suggests that remaining CDK13 activity, or off-target activity on other transcription-associated kinases such as JNK1/2/3 (identified in Supplementary Table 1 and Data Set 2) or other unknown off-targets may also account for this discrepancy. Reference: Nat Chem Biol. 2016 Oct; 12(10): 876–884. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033074/

In vivo activity:

Because THZ531 is not optimized for in vivo studies, this study used the parental compound, THZ1. Olaparib and THZ1 as single agents each significantly decreased tumor growth rate and extended the survival of the mice (median survival: 18 days in vehicle, 32 days in THZ1, and 28 days in the olaparib groups) (Figures 6A and 6B). A striking decreased tumor growth rate was observed when both drugs were used in combination (Figure 6A), and the combination treatment significantly extended survival compared with the vehicle control or either single agent (Figure 6B). Seventy percent of mice in the combination arm were still alive by day 40 when treatment was ended (Figure 6B). Reference: Cancer Cell. 2018 Feb 12;33(2):202-216.e6. https://pubmed.ncbi.nlm.nih.gov/29358035/

	Solvent	mg/mL	mM
Solubility
	DMSO	17.2	30.73
	DMF	30.0	53.76
	Ethanol	25.0	44.80

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 558.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Iniguez AB, Stolte B, Wang EJ, Conway AS, Alexe G, Dharia NV, Kwiatkowski N, Zhang T, Abraham BJ, Mora J, Kalev P, Leggett A, Chowdhury D, Benes CH, Young RA, Gray NS, Stegmaier K. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell. 2018 Feb 12;33(2):202-216.e6. doi: 10.1016/j.ccell.2017.12.009. Epub 2018 Jan 18. PMID: 29358035; PMCID: PMC5846483. 2. Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, Ficarro SB, Elkins JM, Liang Y, Hannett NM, Manz T, Hao M, Bartkowiak B, Greenleaf AL, Marto JA, Geyer M, Bullock AN, Young RA, Gray NS. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84. doi: 10.1038/nchembio.2166. Epub 2016 Aug 29. PMID: 27571479; PMCID: PMC5033074. 3. Iniguez AB, Stolte B, Wang EJ, Conway AS, Alexe G, Dharia NV, Kwiatkowski N, Zhang T, Abraham BJ, Mora J, Kalev P, Leggett A, Chowdhury D, Benes CH, Young RA, Gray NS, Stegmaier K. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell. 2018 Feb 12;33(2):202-216.e6. doi: 10.1016/j.ccell.2017.12.009. Epub 2018 Jan 18. PMID: 29358035; PMCID: PMC5846483.

In vitro protocol:

In vivo protocol:

1: Zhang T, Kwiatkowski N, Olson CM, Dixon-Clarke SE, Abraham BJ, Greifenberg AK, Ficarro SB, Elkins JM, Liang Y, Hannett NM, Manz T, Hao M, Bartkowiak B, Greenleaf AL, Marto JA, Geyer M, Bullock AN, Young RA, Gray NS. Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84. doi: 10.1038/nchembio.2166. PubMed PMID: 27571479; PubMed Central PMCID: PMC5033074.